---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Access and distribution"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Access and distribution. Topics: Expanded access; U.S. commercialization plans and specialty sales force; Commercialization outside the United States by Servier; Manufacturing, packaging, and distribution through contract manufacturers; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/access-and-distribution"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Expanded access

> “Currently, participation in a clinical trial is the only way to receive any of IDEAYA’s investigational drugs.”
> “Until further safety and efficacy data become available, we will not be making these investigational drugs available in other ways.”

Source: [IDEAYA Biosciences clinical trials and expanded access policy](https://www.ideayabio.com/clinical-trials)

<a id="topic-2.1.2.11-2"></a>

### U.S. commercialization plans and specialty sales force

> “However, we have initiated planning and preparation for potential commercial operations, including for sales, marketing and market access capabilities, subject to the results of our Phase 2/3 clinical trial for darovasertib (OptimUM-02) and required regulatory approvals.”
> “We believe a moderately sized specialty sales force, supported by effective marketing and sales management organizations, would enable us to reach healthcare professionals who specialize in the care of the patient populations for darovasertib and our other product candidates.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

### Commercialization outside the United States by Servier

> “Under the Servier Licensing Agreement, Servier will be responsible for the commercialization of darovasertib outside of the U.S.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

### Manufacturing, packaging, and distribution through contract manufacturers

> “We have an agreement with STA Pharmaceutical Hong Kong Limited Pharmaceutical (STA Pharmaceutical), and Yuhan Corporation for the synthesis of the API for darovasertib, and agreements with STA Pharmaceutical and Patheon Inc. for formulation and manufacturing of darovasertib drug product.”
> “We have established arrangements with CMOs as well for packaging, labeling and distribution of darovasertib, IDE397, and IDE161.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

### Guideline and compendia listing as a route to payer coverage in HLA-A∗02:01-positive disease

> “IDEAYA also plans to publish data from OptimUM-01 for potential inclusion in the clinical practice guidelines to support the use of the combination in certain HLA*A2:01-positive mUM patients.”
> “Inclusion in the clinical practice guidelines, if achieved, is intended to provide healthcare professionals with an evidence-based rationale to consider use of darovasertib in appropriate patients and may support payer coverage for such patients.”

Source: [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

> “To seek inclusion in clinical practice guidelines and compendia”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.11-6"></a>

### Specialty pharmacy distribution, pricing, and patient assistance

No evidence found.

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
